Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio.
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
RallyBio tries again for reverse merger, this time with Avenzo
A turning point for pancreatic cancer patients
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
Abivax share plunge may change deal outlook
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Analysts see the biotech company as a prime takeover target and several pharma giants have been rumored as potential buyers.
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.
